Treatment options in myelodysplastic syndromes: A new frontier

Journal of Chemotherapy

Volumn 20, Issue 3, 2008, Pages 291-296

  Santini, V ^a   Gozzini, A ^a   Bosi, A ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Epigenetic drugs; Growth factors; Immunosuppressive agents; Myelodysplastic syndromes; Tyrosine kinase inhibitors

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMG 153; ANTINEOPLASTIC AGENT; AZACITIDINE; CYCLOSPORIN; CYTARABINE; DASATINIB; ETANERCEPT; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; RETINOIC ACID; SODIUM PHENYLBUTYRATE; SUBERANOYL HYDROXAMIC ACID; THALIDOMIDE; THYMOCYTE ANTIBODY; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; APLASTIC ANEMIA; APOPTOSIS; BLAST CELL; BLEEDING; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CUTANEOUS T CELL LYMPHOMA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; EPIGENETICS; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; INFECTION; LIFE EXPECTANCY; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; NEUTROPENIA; PALLIATIVE THERAPY; PROGNOSIS; REFRACTORY ANEMIA; REVIEW; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 47349094477     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.3.291     Document Type: Review

References (42)

1. Trost D, Hildebrandt B, Beier M, et al. Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia. Cancer Genet Cytogenet 2006; 165, 1: 51-63.
2. Look AT. Molecular Pathogenesis of MDS. Hematology Am Soc Hematol Educ Program 2005; 156-60.
3. Silverman L. Myelodysplastic syndromes.In: Kue DW, Weichselbaum RR, Bast RC, et al. (eds). Cancer Medicine, 6th ed Hamilton (Canada): BC Decker Inc, 2003.
4. Corey SJ, Minden MD, Barber DL, et al. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007; 7, 2: 118-29.
5. Bennett JM and Komrokji RS. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology 2005; 10, Suppl 1: 258-69.
6. Santini V. New therapies in myelodysplastic syndromes. Am Soc Clin Oncol Educ Program 2007.
7. Vardiman JW. Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2006; 199-204.
8. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89, 6: 2079-88.
9. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23, 30: 7594-603.
10. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108, 2:419-25.
11. Greenberg PL, Baer MR, Bennett JM, et al. Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006; 4, 1: 58-77.
12. Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94, 2: 288-99.
13. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107, 9: 3455-62.
14. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol 1998; 103, 4: 1070-4.
15. Mannone L, Gardin C, Quarre MC, et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 2006; 133, 5: 513-9.
16. Musto P, Lanza F, Balleari E, et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 2005; 128, 2: 204-9.
17. Stasi R, Abruzzese E, Lanzetta G, et al. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 2005; 16, 12: 1921-7.
18. Molldrem JJ, Caples M, Mavroudis D, et al. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997; 99, 3:699-705.
19. Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002; 100, 5:1570-4.
20. Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 2007; 21, 7: 1436-41.
21. Santini V, Gozzini A, Scappini B, et al. Searching for the magic bullet against cancer: the butyrate saga. Leuk Lymphoma 2001; 42, 3:275-89.
22. Gore SD, Weng LJ, Figg WD, et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 2002; 8, 4: 963-70.
23. Kuendgen A, Knipp S, Fox F, et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 2005; 84 Suppl 13: 61-6.
24. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993; 7 Suppl 1: 21-9.
25. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24, 24: 3895-903.
26. Fenaux P, Mufti G, Santini V, et al. Azacitidine treatment prolongs overall survival in higher risk MDS patients compared with conventional care regimens: results of the AZA-001 phase III study" Blood 2008; 110: abst 817.
27. Gore SD. Combination therapy with DNA methyltrans-ferase inhibitors in hematologic malignancies. Nat Clin Pract Oncol 2005; 2, Suppl 1: S30-5.
28. Ruter B, Wijermans PW and Lubbert M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2′-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer 2006; 106, 8: 1744-50.
29. Wijermans PW, Lubbert M, Verhoef G, et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005; 84, Suppl 13: 9-17.
30. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109, 1: 52-7.
31. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106, 8: 1794-803.
32. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2-deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108, 10: 3271-9.
33. Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol. 2007; 25: 3884-91.
34. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352, 6: 549-57.
35. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355, 14: 1456-65.
36. Stover EH, Chen J, Lee BH, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIPlLl-PDGFRalpha in vitro and in vivo. Blood 2005; 106, 9: 3206-13.
37. Ceesay MM, Lea NC, Ingram W, et al. The JAK2 V617F mutation is rare in RARS but common in RARS-T. Leukemia 2006; 20, 11: 2060-1.
38. Cutler CS, Lee SJ, Greenberg P, et al A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004; 104(2): 579-85.
39. Valent P, Horny HP, Bennett JM, et al Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res. 2007; 31(6): 727-36.
40. de Witte T, Suciu S, Brand R, et al. Autologous stem cell transplantation in myelodysplastic syndromes.Semin Hematol. 2007; 44(4): 274-7.
41. Al-Ali HK, Brand R, van Biezen A, et al. A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia. 2007; 21(9): 1945-51.
42. de Witte T, Oosterveld M, Muus P. Autologous and allogeneic stem cell transplantation for myelodysplastic syndrome. Blood Rev. 2007; 21(1): 49-59.